查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1500309

全球肺癌液体活检市场 2024-2031

Global Lung Cancer Liquid Biopsy Market 2024-2031
出版日期: | 出版商: Orion Market Research | 英文 135 Pages | 商品交期: 2-3个工作天内

价格

预计在预测期内（2024-2031年），肺癌液体活检市场将以13.4%的复合年增长率显着增长。肺癌液体活检是一种利用体液中的生物标记检测和监测肺癌的诊断技术。它是微创、即时的，并提供全面的肿瘤分析。它有助于早期检测、治疗反应、疾病进展评估和治疗抗药性识别。肿瘤学的这项进步改善了患者的治疗效果。

市场动态

目录

第 1 章：报告摘要

  • 目前行业分析及成长潜力展望
  • 研究方法和工具
  • 市场区隔
    • 按细分
    • 按地区

第 2 章：市场概述与见解

  • 报告范围
  • 分析师见解和当前市场趋势
    • 主要行业趋势
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • CareDx, Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Eurofins Scientific SE
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Qiagen NV
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 关键策略分析

第 4 章：市场细分

  • 按 Biomarker 分類的全球肺癌液体活检治疗市场
    • 循环核酸
    • CTC
    • 外泌体/微泡
    • 循环蛋白质
  • 全球肺癌液体活检治疗市场（按应用）
    • 治疗选择
    • 治疗监测
    • 早期癌症筛检
    • 復发监测
  • 全球肺癌液体活检治疗市场（按最终用户）
    • 医院和实验室
    • 专科诊所
    • 学术和研究中心
  • 全球肺癌液体活检治疗市场（按产品）
    • 仪器
    • 耗材套件和试剂
    • 软体和服务

第 5 章：区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区
    • 拉丁美洲
    • 中东和非洲

第 6 章：公司简介

  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Exact Sciences Corp.
  • Guardant Health
  • Immucor
  • LungLife AI, Inc.
  • MDxHealth
  • Menarini Silicon Biosystems
  • Myriad Genetics, Inc.
  • Thermo Fisher Scientific Inc.
Product Code: OMR2028579

Global Lung Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report by Biomarker (Circulating Nucleic Acids, CTC, Exosomes/Microvesicles, Circulating Proteins), by Application (Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring), by End-User (Hospitals and Laboratories, Specialty Clinics, Academic and Research Centers), by Product (Instruments, Consumables Kits and Reagents, Software and Services) Forecast Period (2024-2031)

The lung cancer liquid biopsy market is anticipated to grow at a significant CAGR of 13.4% during the forecast period (2024-2031). Lung cancer liquid biopsy is a diagnostic technique for lung cancer detection and monitoring, using biomarkers in bodily fluids. It is minimally invasive, real-time, and provides comprehensive tumor profiling. It aids in early detection, treatment response, disease progression assessment, and therapy resistance identification. This advancement in oncology improves patient outcomes.

Market Dynamics

Rapid Advancements in Technology

Ongoing advancements in technology, such as next-generation sequencing (NGS) and digital PCR, are enhancing the sensitivity, specificity, and accuracy of liquid biopsy assays, driving adoption in clinical practice. For instance, in December 2022, Agilent Technologies Inc. received FDA approval for Agilent Resolution ctDx FIRST as a companion diagnostic used to identify advanced non-small lung cancer in patients.

Drug Development and Clinical Trials

Globally, liquid biopsy is playing a crucial role in drug development and clinical trials by enabling the identification of biomarkers for patient selection, monitoring treatment response, and assessing drug resistance, thereby accelerating the development of targeted therapies and immunotherapies for lung cancer. The increasing funding for drug development in universities and research organizations is making a significant contribution to the growth of the global market.

Market Segmentation

Our in-depth analysis of the global lung cancer liquid biopsy market includes the following segments by type, product, and technology,

  • Based on biomarkers, the market is segmented into circulating nucleic acids, CTC, exosomes/microvesicles, circulating proteins
  • Based on application, the market is segmented into therapy selection, treatment monitoring, early cancer screening, recurrence monitoring
  • Based on end-user, the market is segmented into hospitals and laboratories, specialty clinics, academic and research centers
  • Based on product, the market is segmented into instruments, consumables kits and reagents, software and services

Therapy Selection is Projected to Emerge as the Largest Segment

The primary factors supporting the segment's growth due to the growing trend towards personalized medicine, targeted therapy adoption, complementary to tissue biopsy, non-invasive and real-time monitoring, clinical evidence, and rapid technological advancements. Liquid biopsy allows for the identification of specific biomarkers and genetic mutations associated with each patient's tumor, enabling clinicians to tailor treatment plans based on their unique molecular profile. It also enhances the accuracy of therapy selection, particularly in cases where tissue biopsy results are inconclusive or unavailable. The increasing body of clinical evidence supporting liquid biopsy for therapy selection in lung cancer and rapid technological advancements like next-generation sequencing and digital PCR further contribute to its growth.

Regional Outlook

The global lung cancer liquid biopsy market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Holds Major Market Share

Among all the regions, North America holds a significant share owing to the presence of advanced healthcare infrastructure, strong research and development ecosystem, regulatory framework, early clinical adoption, large patient population, high disease burden, access to capital, and global leadership in biotechnology and healthcare innovation. The US and Canada have well-established regulatory frameworks for medical devices and diagnostic tests, ensuring the safety, efficacy, and quality of liquid biopsy assays. The region's culture of early adoption of medical technologies, high healthcare spending, patient demand for advanced diagnostics, and supportive reimbursement environments drive clinicians to incorporate liquid biopsy into standard cancer care protocols.

The major companies serving the global lung cancer liquid biopsy market include Eurofins Scientific, MDxHealth, CareDx, Immucor, Thermo Fisher Scientific Inc., Menarini Silicon Biosystems, Qiagen, Guardant Health, Exact Sciences Corporation, among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers, and acquisitions to stay competitive in the market. For Instance, in July 2023, Menarini Silicon Biosystems launched its new CellSearch CTC test with the biomarker- DLL3 for the treatment of small-cell lung cancer. This launch helped the organization to expand its development of liquid biopsy assays.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Industry Trends
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. CareDx, Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Eurofins Scientific SE
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Qiagen NV
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Lung Cancer Liquid Biopsy Treatment Market by Biomarker
    • 4.1.1. Circulating Nucleic Acids
    • 4.1.2. CTC
    • 4.1.3. Exosomes/Microvesicles
    • 4.1.4. Circulating Proteins
  • 4.2. Global Lung Cancer Liquid Biopsy Treatment Market by Application
    • 4.2.1. Therapy Selection
    • 4.2.2. Treatment Monitoring
    • 4.2.3. Early Cancer Screening
    • 4.2.4. Recurrence Monitoring
  • 4.3. Global Lung Cancer Liquid Biopsy Treatment Market by End-User
    • 4.3.1. Hospitals and Laboratories
    • 4.3.2. Specialty Clinics
    • 4.3.3. Academic and Research Centers
  • 4.4. Global Lung Cancer Liquid Biopsy Treatment Market by Product
    • 4.4.1. Instruments
    • 4.4.2. Consumables Kits and Reagents
    • 4.4.3. Software and Services

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World
    • 5.4.1. Latin America
    • 5.4.2. Middle East & Africa

6. Company Profiles

  • 6.1. Agilent Technologies, Inc.
  • 6.2. Bio-Rad Laboratories, Inc.
  • 6.3. Exact Sciences Corp.
  • 6.4. Guardant Health
  • 6.5. Immucor
  • 6.6. LungLife AI, Inc.
  • 6.7. MDxHealth
  • 6.8. Menarini Silicon Biosystems
  • 6.9. Myriad Genetics, Inc.
  • 6.10. Thermo Fisher Scientific Inc.

LIST OF TABLES

  • 1. Global Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Biomarker, 2023-2031 ($ Million)
  • 2. Global Circulating Nucleic Acids Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 3. Global CTC Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 4. Global Exosomes/Microvesicles Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 5. Global Circulating Protein Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 6. Global Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Application 2023-2031 ($ Million)
  • 7. Global Lung Cancer Liquid Biopsy Treatment Therapy Session Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 8. Global Lung Cancer Liquid Biopsy Treatment for Treatment Monitoring Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 9. Global Lung Cancer Liquid Biopsy Treatment for Early Cancer Screening Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 10. Global Lung Cancer Liquid Biopsy Treatment For Recurrence Monitoring Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 11. Global Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 12. Global Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By end-User, 2023-2031 ($ Million)
  • 13. Global Lung Cancer Liquid Biopsy Treatment for Hospitals And Laboratories Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 14. Global Lung Cancer Liquid Biopsy Treatment for Specialty Clinics Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 15. Global Lung Cancer Liquid Biopsy Treatment for Academics And Research Centers Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 16. Global Lung Cancer Liquid Biopsy Treatment Market Research And Analysis Byproduct 2023-2031 ($ Million)
  • 17. Global Lung Cancer Liquid Biopsy Treatment for Instruments Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 18. Global Lung Cancer Liquid Biopsy Treatment for Consumables Kits And Reagents Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 19. Global Lung Cancer Liquid Biopsy Treatment For Software And Services Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 20. Global Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Product 2023-2031 ($ Million)
  • 21. North American Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Country, 2023-2031 ($ Million)
  • 22. North American Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Biomarker, 2023-2031 ($ Million)
  • 23. North American Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Application, 2023-2031 ($ Million)
  • 24. North American Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Product, 2023-2031 ($ Million)
  • 25. North American Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By End-User, 2023-2031 ($ Million)
  • 26. European Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Country, 2023-2031 ($ Million)

27. European Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Biomarker, 2023-2031 ($ Million

  • 28. European Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Application, 2023-2031 ($ Million)
  • 29. European Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Product, 2023-2031'1 ($ Million)
  • 30. European Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By End-User, 2023-2031 ($ Million)
  • 31. Asia-Pacific Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Country, 2023-2031 ($ Million)
  • 32. Asia-Pacific Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Biomarker, 2023-2031 ($ Million)
  • 33. Asia-Pacific Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Application, 2023-2031 ($ Million)
  • 34. Asia-Pacific Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Product, 2023-2031 ($ Million)
  • 35. Asia-Pacific Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By End-User, 2023-2031 ($ Million)
  • 36. Rest Of The World Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 37. Rest Of The World Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Biomarker, 2023-2031 ($ Million)
  • 38. Rest Of The World Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Application, 2023-2031 ($ Million)
  • 39. Rest Of The World Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Product, 2023-2031 ($ Million)
  • 40. Rest Of The World Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By End-User, 2023-2031 ($ Million)

LIST OF FIGURES

  • 1. Global Lung Cancer Liquid Biopsy Treatment Market Share By Biomarker, 2023 Vs 2031 (%)
  • 2. Global Circulating Nucleic Acids Lung Cancer Liquid Biopsy Treatment Market Share By Region, 2023 Vs 2031 (%)
  • 3. Global CTC Lung Cancer Liquid Biopsy Treatment Market Share By Region, 2023 Vs 2031 (%)
  • 4. Global Exosomes/Microvesicles Lung Cancer Liquid Biopsy Treatment Market Share By Region, 2023 Vs 2031 (%)
  • 5. Global Circulating Protein Lung Cancer Liquid Biopsy Treatment Market Share By Region, 2023 Vs 2031 (%)
  • 6. Global Lung Cancer Liquid Biopsy Treatment Market Share By Application, 2023 Vs 2031 (%)
  • 7. Global Therapy Session Lung Cancer Liquid Biopsy Treatment Market Share By Region, 2023 Vs 2031 (%)

8. Global Treatment Monitoring Lung Cancer Liquid Biopsy Treatment Market Share By Region, 2023 Vs 2031 (%)-

  • 9. Global Early Cancer Screening Lung Cancer Liquid Biopsy Treatment Market Share By Region, 2023 Vs 2031 (%)
  • 10. Global Recurrence Monitoring Applied Membranes Treatment Market Share By Region, 2023 Vs 2031 (%)
  • 11. Global Lung Cancer Liquid Biopsy Treatment Market Share By End-User, 2023 Vs 2031 (%)
  • 12. Global Lung Cancer Liquid Biopsy Treatment In Hospitals And Laboratories Market Share By Region, 2023 Vs 2031 (%)
  • 13. Global Lung Cancer Liquid Biopsy Treatment In Specialty Clinics Market Share By Region, 2023 Vs 2031 (%)
  • 14. Global Lung Cancer Liquid Biopsy Treatment In Academics And Research Centers Market Share By Region, 2023 Vs 2031 (%)
  • 15. Global Lung Cancer Liquid Biopsy Treatment Market Share By Product, 2023 Vs 2031 (%)
  • 16. Global Lung Cancer Liquid Biopsy Treatment Instruments Market Share By Region, 2023 Vs 2031 (%)
  • 17. Global Lung Cancer Liquid Biopsy Treatment Consumables Kits And Reagents Market Share By Region, 2023 Vs 2031 (%)
  • 18. Global Lung Cancer Liquid Biopsy Treatment Software And Services Market Share By Region, 2023 Vs 2031 (%)
  • 19. Global Lung Cancer Liquid Biopsy Treatment Market Share By Region, 2023 Vs 2031 (%)
  • 20. Us Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
  • 21. Canada Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
  • 22. UK Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
  • 23. France Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
  • 24. Germany Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
  • 25. Italy Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
  • 26. Spain Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
  • 27. Rest Of Europe Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
  • 28. India Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
  • 29. China Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
  • 30. Japan Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
  • 31. South Korea Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
  • 32. Rest Of Asia-Pacific Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
  • 33. Latin America Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
  • 34. Middle East And Africa Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)